Study to Evaluate the Efficacy and Safety of SYSA1901 vs. Perjeta® of HER2-Positive Breast Cancer

NCT05720026 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

560

Enrollment

INDUSTRY

Sponsor class

Conditions

HER2-positive Breast Cancer

Interventions

DRUG: SYSA1901
DRUG: Pertuzumab
DRUG: Trastuzumab
DRUG: Docetaxel

Sponsor

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.